Planta Med 2013; 79(18): 1756-1761
DOI: 10.1055/s-0033-1351099
Natural Product Chemistry
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Secondary Metabolites from Eupenicillium parvum and Their in Vitro Binding Affinity for Human Opioid and Cannabinoid Receptors

Francisco León
1   Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, MS, USA
,
Jiangtao Gao
1   Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, MS, USA
,
Olivia R. Dale
1   Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, MS, USA
,
Yunshan Wu
1   Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, MS, USA
,
Eman Habib
1   Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, MS, USA
2   Department of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Suez, Egypt
,
Afeef S. Husni
1   Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, MS, USA
,
Robert A. Hill
3   National Centre for Advanced Bio-Protection Technologies, Lincoln University, Lincoln, New Zealand
,
Stephen J. Cutler
1   Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, MS, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 11. April 2013
revised 08. Oktober 2013

accepted 25. Oktober 2013

Publikationsdatum:
28. November 2013 (online)

Preview

Abstract

Phytochemical investigation of the soil microfungus Eupenicillum parvum led to the isolation of two new compounds: a chromone derivative euparvione (1) and a new mycophenolic derivative euparvilactone (2), as well as thirteen known compounds. The structures of the new compounds were elucidated by means of extensive IR, NMR, and MS data and by comparison of data reported in the literature. The structure of the known compound 6 was confirmed by X-ray crystallography. Several isolated compounds were evaluated for in vitro binding assays using opioid receptors (subtypes δ, κ, and µ) and cannabinoid receptors (CB1 and CB2). Compound 10 displayed the best selective µ-opioid receptor and CB1 receptor binding affinities showing values of 47 % and 52 % at a 10 µM concentration, respectively. These findings provide insight into the potential therapeutic utility of this class of compounds.

Supporting Information